A Phase 3 interventional study of Nivolumab and Epacadostat in Lung Cancer, sponsored by Incyte Corporation. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-13.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 111th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 55th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 24 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 63 that completed or were terminated, 44 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation: 1 open now, 1 under way, none of them phase 3. Of 26 finished, 19 (73%) have results posted.
Among the 30 studies in Carcinoma, Non-Small-Cell Lung by Incyte Corporation, this one is the 27th largest by enrollment, is one of 6 that started in 2017, is one of 3 in phase 3, and was the 17th registered.
Incyte Corporation’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2014.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Incyte Corporation’s 30 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
This study's enrollment of 2 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab plus epacadostat in combination with platinum doublet
Drug: Nivolumab · Drug: Epacadostat · Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Pemetrexed
Platinum doublet chemotherapy
Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Pemetrexed
Nivolumab plus placebo in combination with platinum doublet chemotherapy.
Drug: Nivolumab · Drug: Placebo · Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Pemetrexed
Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
Also known as: BMS-936558
Epacadostat administered orally at the protocol-defined dose twice daily.
Also known as: INCB024360
Matching placebo for epacadostat administered orally twice daily.
Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
Overall Survival (OS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)
Defined as the time from randomization to the date of death from any cause.
Time frame: Approximately 38 months
Progression-free Survival (PFS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)
Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review, or death due to any cause, whichever occurs first.
Time frame: Approximately 25 months
Objective Response Rate (ORR) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)
Defined as the proportion of participants who achieve a confirmed best response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by blinded independent central review.
Time frame: Approximately 25 months
Duration of Response (DOR) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B)
Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.
Time frame: Approximately 25 months
Estimate of OS of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)
Defined as the time from randomization to the date of death from any cause.
Time frame: Approximately 38 months
Estimate of PFS of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)
Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review or death due to any cause, whichever occurs first.
Time frame: Approximately 25 months
Estimate of ORR of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)
Defined as the proportion of participants who achieve a confirmed best response of CR or PR per RECIST v1.1 criteria as assessed by blinded independent central review.
Time frame: Approximately 25 months
Estimate of DOR of Nivolumab and Placebo in Combination With Chemotherapy (Arm C)
Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.
Time frame: Approximately 25 months
Approximately 630 participants were planned to be randomized. Prior to the termination of the study, 2 participants were randomized to the Platinum Doublet Chemotherapy arm (Arm B) and treated.
| Milestone | Nivolumab + Epacadostat/Platinum Doublet Chemotherapy | Platinum Doublet Chemotherapy | Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy |
|---|---|---|---|
| Started | 0 | 2 | 0 |
| Completed | 0 | 1 | 0 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Administrative reason by the sponsor | 0 | 1 | 0 |
Defined as the time from randomization to the date of death from any cause.
No measurements were reported for this outcome.
Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review, or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
Defined as the proportion of participants who achieve a confirmed best response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria as assessed by blinded independent central review.
No measurements were reported for this outcome.
Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
Defined as the time from randomization to the date of death from any cause.
No measurements were reported for this outcome.
Defined as the time between the date of randomization and the first date of documented progression assessed by blinded independent central review or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
Defined as the proportion of participants who achieve a confirmed best response of CR or PR per RECIST v1.1 criteria as assessed by blinded independent central review.
No measurements were reported for this outcome.
Defined as the time between the date of first confirmed response and the date of the first documented tumor progression (per RECIST v1.1) assessed by blinded independent central review or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
Collected over From the initiation of study treatment until 30 days after last dose of study treatment or up to study termination date 22May2018.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab + Epacadostat/Platinum Doublet Chemotherapy | — | — | — |
| Platinum Doublet Chemotherapy | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy | — | — | — |
| Event | Nivolumab + Epacadostat/Platinum Doublet Chemotherapy | Platinum Doublet Chemotherapy | Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy |
|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | — | 1/2 | — |
| Back painMusculoskeletal and connective tissue disorders | — | 1/2 | — |
| OsteomyelitisMusculoskeletal and connective tissue disorders | — | 1/2 | — |
| Event | Nivolumab + Epacadostat/Platinum Doublet Chemotherapy | Platinum Doublet Chemotherapy | Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy |
|---|---|---|---|
| ConstipationGastrointestinal disorders | — | 2/2 | — |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | — | 1/2 | — |
| Flank painMusculoskeletal and connective tissue disorders | — | 1/2 | — |
| NauseaGastrointestinal disorders | — | 1/2 | — |
| VomitingGastrointestinal disorders | — | 1/2 | — |
| Weight decreasedInvestigations | — | 1/2 | — |
| AnaemiaBlood and lymphatic system disorders | — | 1/2 | — |
| HypotensionVascular disorders | — | 1/2 | — |
| PyrexiaGeneral disorders | — | 1/2 | — |
| ThrombocytopeniaBlood and lymphatic system disorders | — | 1/2 | — |
All randomized participants.
| Age, Categorical(Participants) | Nivolumab + Epacadostat/Platinum Doublet Chemotherapy | Platinum Doublet Chemotherapy | Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 2 | 0 | 2 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Nivolumab + Epacadostat/Platinum Doublet Chemotherapy | Platinum Doublet Chemotherapy | Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 0 | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Nivolumab + Epacadostat/Platinum Doublet Chemotherapy | Platinum Doublet Chemotherapy | Nivolumab + Placebo Combination/Platinum Doublet Chemotherapy | Total |
|---|---|---|---|---|
| White or Caucasian | 0 | 2 | 0 | 2 |
Plan to share: No
Ran from Dec 2017 to primary completion in May 2018, 4 months.
Results were first posted in Jun 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Epacadostat
Carcinoma, Non-Small-Cell Lung →